sur Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations and Kuano Collaborate on PNKP Inhibitor Development
On November 18, 2025, Onco-Innovations Limited announced a pilot project partnering with Kuano Ltd. The collaboration aims to accelerate the development of PNKP Inhibitor Technology, also known as A83B4C63. This initiative utilizes advanced molecular modeling and AI-driven compound design to refine compound architecture and expand the library of optimized analogs, thus enhancing the potential of developing selective and potent inhibitors.
Kuano will employ its quantum-ready analytics platform to provide detailed insights into PNKP inhibition. The collaboration is expected to guide structure optimization, generating potential candidates for Onco's next-generation therapeutics. The pilot project will run through Q4 2025, focusing on enhancing understanding through quantum-level analytics.
This strategic move is part of Onco-Innovations' goal to lead in next-generation oncology.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Onco-Innovations Limited